Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored infliximab treatment for active luminal Crohn's disease
NL-OMON39579Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in Crohn's disease (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Corticosteroid-free remission with endoscopic healing and no surgery at week 54. Started Sep 2012; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON39579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39579.